• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

mathias.azevedobastianbress@unimelb.edu.au

Credentials


Position
Honorary (Senior Fellow)
The Sir Peter MacCallum Department of Oncology
ORCID

0000-0002-9718-9596

Mr Mathias Azevedo Bastian Bressel

Honorary (Senior Fellow)
The Sir Peter MacCallum Department of Oncology

292 Scholarly works
0 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma.
    DOI: 10.1038/s41467-026-74255-x
  • 2026

    Journal article

    FAPI-CUP: A prospective cohort study of patients with cancer of unknown primary (CUP) to evaluate a novel radiotracer, fibroblast activated protein (FAPI), targeting cancer-associated fibroblasts for primary site detection.
    DOI: 10.1200/jco.2026.44.16_suppl.3072
  • 2026

    Journal article

    Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials
    DOI: 10.1016/S1470-2045(26)00170-1
  • 2026

    Journal article

    IGNITE-Cerala: A phase II signal-seeking trial of ceralasertib targeting recurrent high-grade serous ovarian cancer with cyclin E1 overexpression with and without gene amplification.
    DOI: 10.1200/jco.2026.44.16_suppl.5587
  • 2026

    Journal article

    Evaluation of Clinical Outcomes and Pattern of Recurrence in Patients with Cutaneous Melanoma and Sentinel Lymph Node Positivity Since the Publication of the MSLT-2 Trial
    DOI: 10.1245/s10434-026-19260-6
  • 2026

    Journal article

    Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study
    DOI: 10.1016/S1470-2045(26)00091-4
  • 2018

    Journal article

    Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma
    DOI: 10.1056/NEJMoa1715519
Mathias Azevedo Bastian Bressel

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    ASO Visual Abstract: Evaluation of Clinical Outcomes and Pattern of Recurrence in Patients With Cutaneous Melanoma and Sentinel Lymph Node Positivity Since the Publication of the MSLT-2 Trial
    DOI: 10.1245/s10434-026-19430-6
  • 2026

    Journal article

    SABR Versus Radiofrequency Ablation and Cryoablation for Primary Renal Cell Carcinoma: An Economic Evaluation of the FASTRACK II Trial
    DOI: 10.1016/j.ijrobp.2025.05.089
  • 2026

    Journal article

    Real-World Endpoints in Stereotactic Body Radiation Therapy Trials for Oligoprogression: Beyond Progression-Free Survival and Overall Survival
    DOI: 10.1016/j.ijrobp.2025.08.009
  • 2026

    Journal article

    Secondary outcomes of the TROG 99.03 randomized trial of systemic therapy after involved-field radiotherapy in early-stage follicular lymphoma, including toxicity, relapse and second malignancy data
    DOI: 10.1016/j.radonc.2026.111388

Acknowledgement of Country

We acknowledge Aboriginal and Torres Strait Islander people as the Traditional Owners of the unceded lands on which we work, learn and live. We pay respect to Elders past, present and future, and acknowledge the importance of Indigenous knowledge in the Academy.

Read about our Indigenous priorities

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Campus locations  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia

facebookIconlinkedinIconinstagramIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy

CRICOS number: 00116K     ABN: 84 002 705 224